New cocktail aims to outsmart pancreatic Cancer's defenses
NCT ID NCT05077800
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding two experimental drugs (elraglusib and losartan) to standard chemotherapy (FOLFIRINOX) can prevent metastatic pancreatic cancer from becoming resistant to treatment. About 70 adults with untreated, advanced pancreatic cancer will receive the combination. The main goal is to see if this approach improves the time before the cancer progresses.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Massachusetts General Hospital
Charlestown, Massachusetts, 02129, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
-
University of Colorado Cancer Center
Aurora, Colorado, 80045, United States
-
University of Washington School of Medicine
Seattle, Washington, 98109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill rouse the immune system against pancreatic cancer?
- Can a smart drug home in on Hard-to-Treat cancers?
- A sound wave that could expose hidden pancreatic cancer?
- Can a Two-Target antibody shrink Hard-to-Treat cancers?
- Targeted chemotherapy pump takes fight directly to pancreatic cancer liver tumors
- Light-Activated therapy targets pancreatic tumors during surgery